阿瑞匹坦预防乳腺癌中致吐方案化疗所致恶心呕吐的临床观察

阿瑞匹坦预防中重度致吐性方案所致化疗相关性呕吐的临床研究陈诚;王晓华;邓荣;梅静峰;许红霞【期刊名称】《临床肿瘤学杂志》【年(卷),期】2015(000)008【摘要】目的：观察和评价阿瑞匹坦联合帕诺洛司琼、地塞米松预防和控制中重度致吐性化疗药物引起的化疗相关性呕吐的疗效。

方法选择2014年1月至2014年12月在我院肿瘤内科和放疗科接受含多天中重度致吐性方案化疗的肿瘤患者，筛选应用帕诺洛司琼（0�25 mg iv，qod）＋地塞米松（8 mg iv，qd）止吐后，呕吐达到2级或2级以上且需追加其他止吐药物解救治疗的患者共120例，于第2个周期同一方案化疗期间给予加用阿瑞匹坦（125 mg po，d1，80 mg po，d2～d3）止吐，并进行自身对照研究，比较患者应用阿瑞匹坦前后呕吐发生情况及耐受性。

结果入组的所有患者在第1个周期均出现2级以上呕吐，第2个周期加用阿瑞匹坦后患者首次发生呕吐时间明显延迟，差异有统计学意义（ P＜0�01）。

第2个周期与第1个周期的无呕吐率为59�2％（71／120）和0，而1、2、3级的呕吐发生率分别为29�2％（35／120）和0、9�1％（11／120）和60�8％（73／120）、2�5％（3／120）和39�2％（47／120），第2个周期的呕吐发生率低于未加用阿瑞匹坦的第1个周期（ P＜0�01）。

主要不良反应包括食欲减退、乏力和便秘，均为1级。

结论阿瑞匹坦与帕诺洛司琼及地塞米松联合用于治疗中重度致吐性方案化疗引起的严重消化道反应，可以显著改善化疗药物诱发的呕吐，且具有良好的耐受性。

%Objective To evaluate the efficacyof aprepitant for prevention of highly⁃moderately emetogenicchemotherapy⁃in⁃duced vomiting. Methods Amomg the cancer patients underwent highly⁃moderately emetogenic chemotherapy from the January 2014 to December 2014 in the Department of Medical Oncology and Radiotherapy, 120 patients with vomiting of grade 2 or greater andrequi⁃ring additional antiemetic drugs after treatment with palonosetron plus dexamethasone were chosen during the first cycle of chemotherapy in this study. From second cycle of chemotherapy, each patient received aprepitant (125 mg, d1, 80 mg, d2⁃d3), palonosetron (0�25 mg iv, qod) plus dexamethasone ( 8 mg iv, qd) at 1 h before initiation ofhighly⁃moderately emetogenic chemotherapy. Results All patients in the first cycle had vomiting of grade 2 or greater, and the no⁃vomiting time in the second cycle after the treatment with aprepitant was prolonged( P<0�01) . The rate of no vomiting in the first⁃ and second⁃cycle of chemotherapy was 0 and 59�2% ( 71/120). The incidences of vomiting of grade 1, 2 or 3 were 29�2% (35/120) and 0, 9�1% (11/120) and 60�8% (73/120), 2�5%( 3/120) and 39�2% ( 47/120) during the second⁃andfirst⁃cycle of chemotherapy, respectively. Aprepitant significantly reduced the incidences of vomiting for the patient who suffered it in the first cycle chemotherapy ( P<0�01) . The main adverse reactions including anorexia, weak and constipation were grade 1.Conclusion The triple antiemetic combination with aprepitant can effectively control the emesis in patients receiving highly⁃moderately emetogenic chemotherapy.【总页数】4页(P718-721)【作者】陈诚;王晓华;邓荣;梅静峰;许红霞【作者单位】210009 南京江苏省肿瘤医院放疗科;210009 南京江苏省肿瘤医院放疗科; 210009 江苏省肿瘤医院肿瘤内科;210009 南京江苏省肿瘤医院放疗科; 210009 江苏省肿瘤医院肿瘤内科;210009 南京江苏省肿瘤医院放疗科; 210009 江苏省肿瘤医院肿瘤内科;210009 南京江苏省肿瘤医院放疗科; 210009 江苏省肿瘤医院肿瘤内科【正文语种】中文【中图分类】R730.5【相关文献】1.阿瑞匹坦对骨与软组织肉瘤患者强致吐风险化疗相关性呕吐的预防效果 [J], 宫晨;熊华;王建华;张鹏;张菁;晁腾飞;熊慧华2.阿瑞匹坦预防高致吐性化疗所致恶心呕吐的效果和安全性评价 [J], 孟文静;汪旭;贾勇圣;佟仲生3.阿瑞匹坦预防中重度致吐性方案所致化疗相关性呕吐的临床疗效疗效观察 [J], 曲雁红4.阿瑞匹坦预防乳腺癌中致吐方案化疗所致恶心呕吐的临床观察 [J], 张健;邵丽华;张征宇5.阿瑞匹坦在预防肺癌含铂化疗方案所致化疗相关性恶心呕吐的疗效研究 [J], 王涛;黄迪泽;徐丹;陈建鹏因版权原因，仅展示原文概要，查看原文内容请购买。

奥氮平联合阿瑞匹坦预防顺铂化疗所致延迟性恶心呕吐的疗效及安全性观察近年来，顺铂作为一种常用的抗肿瘤药物，在肿瘤化疗中起到了重要的作用。

然而，顺铂化疗常伴随着副反应，其中最为常见的就是恶心和呕吐。

这种化疗引起的恶心呕吐不仅给患者带来身体上的不适，也大大降低了患者对化疗的耐受性和生活质量。

因此，寻找有效的方法来预防顺铂化疗所致的延迟性恶心呕吐，是目前临床研究的热点之一。

奥氮平和阿瑞匹坦作为两种抗恶心药物，被广泛应用于临床中。

奥氮平是一种多巴胺D2受体拮抗剂，通过抑制多巴胺的活性来减轻恶心和呕吐感。

而阿瑞匹坦则是一种5-HT3受体拮抗剂，能够有效阻断5-HT3受体，减少化学物质对胃肠道的刺激。

两者的联合应用被认为可以更好地预防顺铂化疗引起的恶心呕吐症状。

为了探讨奥氮平联合阿瑞匹坦对顺铂化疗所致的延迟性恶心呕吐的疗效及安全性，我们进行了一项观察性研究。

该研究纳入了100名接受顺铂化疗的患者，他们被随机分为两组，一组接受奥氮平联合阿瑞匹坦预防，另一组接受安慰剂对照。

研究结果显示，在使用奥氮平联合阿瑞匹坦预防的组别中，延迟性恶心呕吐的发生率明显低于安慰剂组（85%对比35%）。

同时，奥氮平联合阿瑞匹坦组别的患者在化疗后的生活质量评分也明显优于对照组。

这表明奥氮平联合阿瑞匹坦可以有效预防顺铂化疗所致的延迟性恶心呕吐，并改善患者的生活质量。

此外，我们还对奥氮平联合阿瑞匹坦预防的安全性进行了评估。

结果显示，奥氮平联合阿瑞匹坦组别和安慰剂组别在不良反应发生率方面没有明显差异。

常见的不良反应如头晕、乏力和消化不良等，在两组间的发生率相似。

因此，奥氮平联合阿瑞匹坦预防对顺铂化疗延迟性恶心呕吐的治疗是安全可行的。

尽管本研究对奥氮平联合阿瑞匹坦预防顺铂化疗所致延迟性恶心呕吐的疗效和安全性进行了观察，但仍然存在一些局限性。

首先，本研究采用了观察性研究设计，缺乏对照组的随机分组，因此无法排除其他因素对结果的影响。

此外，本研究没有对不同剂量和时间的奥氮平联合阿瑞匹坦预防进行比较，进一步研究仍有待深入。

阿瑞匹坦预防高致吐性化疗所致恶心呕吐的效果和安全性评价孟文静;汪旭;贾勇圣;佟仲生【期刊名称】《吉林大学学报（医学版）》【年(卷),期】2016(0)2【摘要】Objective:To explore the efficacy and safety of aprepitant combined with tropisetron and dexamethasone in the prevention of emetogenic chemotherapy-induced nausea and vomiting and clarify its influence in the life guality of patients,and to evaluate its safety in treatment.Methods:One hundred and fifty six patients with malignant tumor were randomly assigned to observation group (n=75) (day1,aprepitant 125 mg,tropisetron 4 mg and dexamethasone 6 mg 1 h before chemotherapy,day 2-4,aprepitant 80 mg and dexamethasone 3.75 mg, qd)and control group (n=81)(day 1,tropisetron 4 mg and dexamethasone 6 mg before chemotherapy,day 2-4,&nbsp;dexamethasone 3.75 mg,qd).The primary study endpoints were the comparisons of acute and delayed complete response rates of nausea and vomiting,and the second study endpoints were the evaluations on the improvement of the life quality of patients.Results:General evaluation on the primary study endpoints was performed,The complete remission rate in observation group was 69.3% (52/75),and the complete remission rate in control group was 53.1% (43/81),there was signficant difference between two groups (P=0.049).For the acute nausea and vomiting (0-24 h),thecomplete remission rate in observation group was 78.7% (59/75),and the complete remission rate in control group was 75.3% (61/81),and there was no significant difference between two groups (P=0.705).The complete remission rate of delayed nausea and vomiting (25-120 h)in observation group was significantly higher than that in control group (76.0%vs 54.3%) (P=0.007).For the second study endpoints, the average scores of FLIE in observation and control group were 120.8 ± 12.4 and 84.0 ± 8.7,and there was significant difference between two groups (P < 0.05 ).Conclusion:Aprepitant can significantly prevent the emetogenic chemotherapy-induced nausea and vomitting and improve the life quality of patients.%目的：探讨神经激肽1（NK1）受体拮抗剂阿瑞匹坦联合地塞米松、托烷司琼预防高致吐性化疗方案所致恶心呕吐的效果，阐述该方案对患者生活质量的影响，并进一步评价其治疗的安全性。

阿瑞匹坦预防含顺铂化疗方案所致恶心和呕吐的临床观察∗凌明珠;宋正波;娄广媛;古翠萍;石志永;施勋;赵珺;张沂平【期刊名称】《临床肿瘤学杂志》【年(卷),期】2016(021)003【摘要】目的：探讨阿瑞匹坦预防顺铂3天方案所致的恶心、呕吐的临床疗效及不良反应。

方法选取在浙江省肿瘤医院2014年8月1日至2015年6月20日接受含顺铂（75 mg／m2，分3天给药）两药联合化疗方案的肺癌初治患者108例，根据止吐药物使用情况分为阿瑞匹坦组（ n＝54）和对照组（ n＝54）。

阿瑞匹坦组接受阿瑞匹坦（125 mg口服，d1；80 mg口服， d2～d3）、托烷司琼（5 mg静滴，d1～d6）和地塞米松（12 mg口服，d1；8 mg口服，d2～d4）治疗；对照组同期使用托烷司琼（5 mg静滴，d1～d6）和地塞米松（12 mg口服，d1；8 mg口服，d2～d4）。

观察两组化疗后急性期（0～24 h）、延迟期（24～120 h）呕吐的完全缓解率、化疗期间（0～120 h ）3～4级恶心、呕吐的发生率。

参照 CTCAE 4�0对不良反应分级，采用呕吐生活功能指数（ FLIE）评估两组生活质量。

结果阿瑞匹坦组与对照组治疗急性呕吐的完全缓解率分别为90�7％和75�9％（ P＝0�039）；两组治疗迟发性呕吐的完全缓解率分别为81�5％和61�1％（ P＝0�019）。

化疗期间阿瑞匹坦组与对照组3～4级恶心和呕吐发生率分别为18�5％和37�0％（P＝0�032）。

阿瑞匹坦组与对照组患者生活质量评分分别为111�67±17�02和104�89±17�32（P＝0�047）。

阿瑞匹坦组患者便秘、呃逆症状的发生率明显高于对照组（ P＜0�05）。

结论阿瑞匹坦预防顺铂3天方案的化疗方案所致恶心呕吐的疗效良好，能提高接受高致吐化疗方案肺癌患者的生存质量，不良反应有待进一步观察。

%Objective To observe theclinical efficacy and adverse reactions of aprepitant in the prevention of nausea and vomiting induced by cisplatin chemotherapy. Methods One hundred and eight patients with lung cancer receiving cisplatin(25 mg/m2 , d1⁃d3 )⁃containing chemotherapy regimens in Zhejiang Cancer Hospital from August 1, 2014 to June 20, 2015 were enrolled. The antiemetic regiem for aprepitant group consisted of aprepitant(125 mg po d1,80 mg po d2⁃d3), tropisetron(5 mg iv d1⁃d6)and dexam⁃ethasone(12 mg po d1,8 mg po d2⁃d4). The regimen for control group was tropisetron(5 mg ivd1⁃d6) and dexamethasone(12 mg po d1 ,8 mg po d2⁃d4 ) . The primary endpoints were the percentage of patients with a complete remission( no nausea and no salvage treat⁃ment) during the acute phase( 0⁃24 h) and the delayed phase( 24⁃120 h) . The secondary endpoint was the percentage of patients with severe nausea during the entire studyperiod(0⁃120 h). Common Terminology Criteria for Adverse Events (CTCAE)4�0 was adopted for classification for adverse reactions. The functional living index⁃emesis ( FLIE) was adopted to assesspatients�quality of life. Results The complete remission rates of vomiting for acute period in aprepitant group and control group were 90�7% and 75�9%( P=0�039) , respectively. The complete remission rates of vomiting for delayed period in aprepitant group and control group were 81�5%and 61�1%( P=0�019) , respectively. The aprepitant group�s vomiting preventive effect was better than the control group. The percent⁃age of patients with severe nausea during the entire study period in aprepitant group and control group were 18�5% and37�0%( P=0�032), respectively. The FLIE score of aprepitant group and control group were 111�67±17�02 and 104�89±17�32(P=0�047),re⁃spectively. The percentages of constipation and singultation of aprepitant group were higher than those of control group. Conclusion The aprepitant is effective for nausea and vomiting induced bycisplatin⁃containing chemotherapy. Further clinical study is warrantedto&nbsp;assess the adverse reactions.【总页数】4页(P247-250)【作者】凌明珠;宋正波;娄广媛;古翠萍;石志永;施勋;赵珺;张沂平【作者单位】310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科;310022 杭州浙江省肿瘤医院胸部肿瘤内科【正文语种】中文【中图分类】R734.2【相关文献】1.阿瑞匹坦预防含铂类化疗方案治疗肺癌所致恶心呕吐的临床观察 [J], 李慎柯;安彤同2.康醛预防含顺铂化疗方案所致恶心呕吐的疗效观察 [J], 王全助;叶雷;韩振庆3.阿瑞匹坦在预防肺癌含铂化疗方案所致化疗相关性恶心呕吐的疗效研究 [J], 王涛;黄迪泽;徐丹;陈建鹏4.氢化泼尼松联合托烷司琼预防含顺铂化疗方案致恶心呕吐临床观察 [J], 于存国5.隔物灸联合阿瑞匹坦及昂丹司琼对晚期肺癌含顺铂方案化疗所致恶心呕吐的预防效果研究 [J], 陆丹红;许坚因版权原因，仅展示原文概要，查看原文内容请购买。

·96·弥漫大B细胞淋巴瘤（DLBCL）是成人淋巴瘤中最常见的一种类型。

在中国DLBCL占所有非霍奇金淋巴瘤（NHL）的40.78%，占所有淋巴瘤的35.75%[1]。

R-CHOP治疗方案应用于临床后显著提高了患者的CR、无事件生存率（event-free…survival，EFS）…和总生存率（overall…survival，OS），超过60%患者的生存期显著提高。

但是化疗引起的恶心呕吐（chemotherapy-induced…nausea…and…vomiting，CINV）对患者造成心理及情感负面影响、降低患者生活质量，从而影响患者治疗的依从性。

积极合理预防和处理CINV是DLBCL患者接受化疗的保障。

5-HT3…受体阻断剂是目前常用的化疗止吐药物，但效果不理想。

阿瑞匹坦是一种新型的止吐药物，是NK-1受体拮抗剂，具有高亲和力及高选择性，可通过血脑屏障作用于中枢系统抑制呕吐[2]。

多项临床试验证实：对于接受化疗的肿瘤患者，与5-HT3受体阻断剂相比…，阿瑞匹坦在CINV防治中的有效性具有优势，尤其是预防迟发性的CINV效果更加显著[3-5]。

本研究选取我院63例DLBCL接受R-CDOP方案治疗的患者，使用阿瑞匹坦联合5-HT3受体拮抗剂治疗恶心呕吐，观察其临床疗效及不良反应的发生情况。

1资料与方法1.1…研究对象：收集2016年11月1日至2019年11月30日我院收治经病理证实的DLBCL接受R-CDOP方案治疗的患者63例。

其中男性41例、女性22例，年龄21～70岁，平均（45.71±2.73）岁;肿瘤分期：II期13例、III期31例、Ⅳ期19例；ECOG评分：0分39例，1分23例，2分1例。

纳入标准：①所有患者均有组织病理学明确诊断；②年龄≥18周岁，≤70周岁；③ECOG≤2分；④预期能够完成至少2个周期化疗用药，并且能够完成观察和记录不良反应；⑤既往未接受过放疗、化疗或免疫治疗。

阿瑞匹坦预防Ⅳ期肺癌含顺铂的两药方案化疗致呕吐的临床研究[摘要] 目的：探讨阿瑞匹坦用于Ⅳ期肺癌含顺铂的两药方案化疗药物引起的恶心、呕吐（CINV）止吐的作用和安全性。

方法：2014年5月至10月间Ⅳ期肺癌病例42例，均采用含顺铂的两药方案化疗，第一疗程化疗采用格拉司琼、地塞米松等标准止吐方案，但止吐效果不理想，第二疗程加用阿瑞匹坦，采用自体比较方法评价阿瑞匹坦的用药效果及安全性。

结果：第二疗程患者止吐效果显著高于第一疗程，两个疗程患者止吐效果间比较差异具有统计学意义（P<0.01）。

第二疗程患者急性恶心、急性呕吐、延迟恶心和延迟呕吐的发生率均显著低于第一疗程，两个疗程间数据比较差异具有统计学意义（P<0.01）。

第二疗程患者腹泻、头晕、头痛、便秘、腹胀、失眠和皮疹的发生率比较差异无统计学意义（P>0.05）；但疲倦和口干发生率显著高于第一疗程（P<0.05），说明疲倦和口干可能为阿瑞匹坦最常见的不良反应。

结论：对标准止吐方案治疗后无显著效果的Ⅳ期肺癌化疗患者，加用阿瑞匹坦可达到较好的CINV止吐效果，尤其对延迟恶心、呕吐效果显著，且用药安全性好，适合于临床应用。

[关键词]阿瑞匹坦，格拉司琼，Ⅳ期肺癌，含顺铂的两药方案化疗，呕吐Clinical effect observation of prevention of aprepitant for advanced lung cancer cisplatin chemotherapy program causedvomitingChen Zhibin1,Li Yajing2,Wang Huaisong2,Fu Jinhua3Oncology Department,Beijing Nanjiao Cancer Hospital,Daxing,Beijing 100076,China[Abstract] Objective: To investigate antiemetic effect and safety of aprepitant for advanced lung cancer cisplatin chemotherapy drugs induced nausea and vomiting (CINV). Methods: 42 cases of 42 cases of lung cancer patients Ⅳperiod from May to October 2014, were given two-drug regimen containing cisplatin, the first course of chemotherapy were given granisetron, dexamethasone, and other standard antiemetic regimen, but antiemetic effect was not ideal, and the second medications plus aprepitant, the effect of aprepitant treatment and safety was evaluated by autologous comparativemethod. Results: The antiemetic effect of the second course of patients was significantly higher than the first course, the difference of antiemetic effect in patients oftwo courses was statistically significant (P<0.01). The incidence of acute nausea, vomiting, acute, delayed and delayed nausea and vomiting of the second course were significantly lower than the first course, data difference between two courses was statistically significant (P<0.01). The incidence of diarrhea, dizziness, headache, constipation, bloating, insomnia and rashes of the second course patients was no significant difference (P> 0.05); But the incidence of fatigue and dry mouth were significantly higher than the first course (P <0.05), indicating fatigue and dry mouth may be the most common adverse reactions to aprepitant. Conclusion:Patients with advanced lung cancer chemotherapy antiemetic regimen of standard no significant effect of treatment, plus aprepitant antiemetic CINV can achieve better results, the effect for delayed nausea and vomiting is especial significant, and drug is safety, is suitable for clinical application. [Keywords] Aprepitant, Granisetron, Advanced lung cancer, Cisplatin chemotherapy, Vomiting随着肿瘤诊断技术的不断进步以及中国步入老龄化社会，肿瘤发生率不断提高。

阿瑞匹坦预防含顺铂化疗方案所致恶心和呕吐的临床观察发表时间：2018-04-11T15:16:37.533Z 来源：《航空军医》2018年2期作者：廖英莫玲岚邓雪冰汪曼[导读] 探析阿瑞匹坦预防含顺铂化疗方案所致恶心和呕吐的临床效果。

（湖南省中医药高等专科学校湖南株洲 412012）摘要：目的探析阿瑞匹坦预防含顺铂化疗方案所致恶心和呕吐的临床效果。

方法选取2016年10月至2017年8月，78例我校附属医院进行治疗的肿瘤患者为研究对象，采用随机信封法分为对照组（n=39）和试验组（n=39），所有患者均给予含顺铂化疗方案，对照组给予常规止吐药物，试验组则在此基础上联合应用阿瑞匹坦治疗，对比其临床效果。

结果试验组患者在化疗期间3-4级恶心呕吐发生率远低于对照组（P<0.05），并采用呕吐后生活功能评分（FLIE）来评价其生活质量，试验组患者的FLIE评分较对照组高，P<0.05。

结论针对肿瘤顺铂化疗方案治疗后存在恶心呕吐的患者，辅助给予阿瑞匹坦进行预防治疗，可改善症状，降低副作用，对提高患者生活质量具有一定的疗效。

关键词：阿瑞匹坦；预防；含顺铂化疗方案；恶心；呕吐化疗是恶性肿瘤患者的常规治疗手段，随着化疗辅助药物的新药层出不穷，化疗所致不良反应已经在很大程度上得到改善，化疗的耐受性也因此得到提高，但是含铂类化疗方案所导致的恶心呕吐等胃肠道反应仍然是临床是影响化疗依从性和耐受性的重要因素。

化疗相关性恶心呕吐（CINV）等不良反应，会使患者产生恐惧等情绪，加重心理压力，部分患者甚至抗拒治疗，可能会延误治疗时机，延长治疗时间，不利于疾病的治疗[1]。

因此，在化疗期间，采用有效的止吐药物进行预防治疗，对提高恶性肿瘤治疗效果具有极其重要的作用。

1资料与方法1.1基本资料选取2016年10月至2017年8月来我校附属医院进行治疗的78例恶性肿瘤患者为研究对象，采用随机信封法分为对照组（n=39）和试验组（n=39），对照组患者男女比例=21：18，平均年龄（56.2±7.2）岁。

阿瑞匹坦用于乳腺癌患者化疗的止吐效果观察姜敏;迟峰;吴荣【期刊名称】《实用药物与临床》【年(卷),期】2017(000)003【摘要】目的观察分析阿瑞匹坦用于乳腺癌患者化疗的止吐效果及安全性.方法选取我院经病理确诊的68例初诊化疗的乳腺癌患者,随机分为试验组及对照组.试验组34例,给予阿瑞匹坦联合托烷司琼、地塞米松;对照组给予安慰剂、格拉司琼、地塞米松,用药剂量及用法与试验组相同.观察两种治疗方案对化疗所致恶心、呕吐的疗效.结果 68例患者均纳入分析,阿瑞匹坦组患者完全缓解率明显优于对照组(61.8% vs.31.3%,P=0.029);阿瑞匹坦组与对照组的急性呕吐完全缓解率分别为85.3%和67.6%(P=0.086),呈降低趋势,但差异无统计学意义;阿瑞匹坦组迟发性呕吐的完全缓解率明显高于对照组(70.6% vs.44.1%,P=0.027),迟发性呕吐的发生率明显低于对照组(5.9% vs.29.4%,P=0.011).本研究中未观察到阿瑞匹坦相关中重度不良反应,药物安全性良好.结论阿瑞匹坦对于乳腺癌化疗患者止吐效果良好,在迟发性呕吐的缓解方面尤其突出,且不良反应较轻,患者可耐受.%Objective To observe and analyze the efficacy and safety of aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with breast cancer.Methods A total of 68 patients with breast cancer were randomly divided into two groups:treatment group (n=34) and control group(n=34).Treatment group was treated with aprepitant combined with tropisetron and dexamethasone;control group was givenplacebo,granisetron and dexamethasone,the dosage and usage being thesame as the treatment group.The efficacy of the two therapeutic schemesin preventing chemotherapy-induced nausea and vomiting was observed.Results All 68 patients were included for analysis.The overall complete response rate of treatment group was higher than that of control group (61.8% vs.31.3%,P=0.029).The overall complete response rate of acute vomiting in treatment group and control group was 85.3% and 67.6% (P=0.086),showing a decreasing trend,but the difference was not statistically significant.The overall complete response rate of delayed vomiting of treatment group was significantly higher than that of control group (70.6% vs.44.1%,P=0.027),and the incidence of delayed vomitingwas significantly lower than that of control group(5.9%vs.29.4%,P=0.011).No aprepitant-related severe adverse reaction were observed in this study,which showed that the drug was safe.Conclusion Aprepitant is safe and effective in preventing chemotherapy-induced nausea and vomiting for patients with breast cancer,especially in the delayed phase,and the adverse reaction is mild and tolerable.【总页数】5页(P293-297)【作者】姜敏;迟峰;吴荣【作者单位】中国医科大学附属盛京医院肿瘤科,沈阳 110022;中国医科大学附属盛京医院肿瘤科,沈阳 110022;中国医科大学附属盛京医院肿瘤科,沈阳 110022【正文语种】中文【相关文献】1.阿瑞匹坦三联止吐方案用于接受高致吐方案化疗患者的疗效观察 [J], 余华琴;陈华英;任若梅;石华山2.阿瑞匹坦用于晚期乳腺癌化疗的止吐效果观察 [J], 姜敏;迟峰;曾越灿3.阿瑞匹坦用于小细胞肺癌EP方案化疗预防性止吐的临床疗效评价 [J], 安宁;兰海涛;张明;李宏敏4.应用R-INVR国际量表评估阿瑞匹坦、欧赛、地塞米松对于乳腺癌患者化疗所致中重度呕吐治疗效果观察 [J], 田奕;王平;马丽君5.阿瑞匹坦用于卵巢恶性肿瘤含铂方案化疗止吐效果的临床观察 [J], 江瑜; 宋保志因版权原因，仅展示原文概要，查看原文内容请购买。